108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
免疫检查点抑制剂联合化疗与贝伐珠单抗联合化疗治疗晚期无驱动基因突变的非鳞状非小细胞肺癌疗效比较：一项回顾性研究
Authors Chen W, Dai Q, Ye Z, Huang Y
Received 21 April 2025
Accepted for publication 17 July 2025
Published 29 July 2025 Volume 2025:18 Pages 4279—4289
DOI https://doi.org/10.2147/JMDH.S535853
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr David C. Mohr
Wanwan Chen,1 Qiang Dai,2 Zhe Ye,3 Yiwei Huang3
1Department of Pathology, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, 325000, People’s Republic of China; 2Department of Oncology, the Third Affiliated Hospital of Wenzhou Medical University (Ruian People’s Hospital), Wenzhou, Zhejiang, 325200, People’s Republic of China; 3Department of Radiotherapy, the Third Affiliated Hospital of Wenzhou Medical University (Ruian People’s Hospital), Wenzhou, Zhejiang, 325200, People’s Republic of China
Correspondence: Yiwei Huang, Email ghp503@126.com
Objective: To compare the efficacy and safety of immune checkpoint inhibitors (ICIs) plus chemotherapy versus bevacizumab plus chemotherapy in advanced driver gene-negative non-squamous non-small cell lung cancer (NS-NSCLC).
Methods: This retrospective cohort study included 199 patients treated from October 2015 to January 2022. Group A (n=103) received ICIs plus chemotherapy (pemetrexed + cisplatin), while Group B (n=96) received bevacizumab plus the same chemotherapy. Outcomes included treatment response, serum tumor markers (CEA, CA-125, CA-199), immunoglobulins (IgA, IgG, IgM), adverse reactions, and survival [progression-free survival (PFS), overall survival (OS)].
Results: Group A had a significantly higher objective response rate (59.22% vs 36.46%, P=0.001). Tumor marker levels decreased more in Group A (P< 0.05), while declines in immunoglobulin levels were less pronounced (P< 0.05). Adverse events were similar between groups (P> 0.05). Group A had a longer median PFS (11.13 vs 7.37 months, P< 0.05), and a non-significant trend toward longer OS (20.87 vs 18.4 months, P=0.159).
Conclusion: ICIs combined with chemotherapy improved treatment efficacy and PFS compared to bevacizumab-based therapy in advanced driver gene-negative NS-NSCLC, with manageable safety and less impact on immune function.
Keywords: immune checkpoint inhibitors, chemotherapy, bevacizumab, non-squamous non-small cell lung cancer, driver gene-negative